Report Detail
Global Dendritic Cell Cancer Vaccine Market Insights, Forecast to 2025
- RnM3539481 |
- 19 June, 2019 |
- Global |
- 120 Pages |
- QYResearch |
- Pharma & Healthcare
Dendritic cells (DCs) refer to rare kind of leukocytes. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells.
The global Dendritic Cell Cancer Vaccine market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Dendritic Cell Cancer Vaccine market based on company, product type, end user and key regions.
This report studies the global market size of Dendritic Cell Cancer Vaccine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Dendritic Cell Cancer Vaccine in these regions.
This research report categorizes the global Dendritic Cell Cancer Vaccine market by top players/brands, region, type and end user. This report also studies the global Dendritic Cell Cancer Vaccine market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Medigene
Activarti
Argos Therapeutics
Batavia Bioservices
Bellicum Pharmaceuticals
Creagene
DanDrit Biotech
DCPrime
Sanpower Corporation (Dendreon)
Elios Therapeutics
Immunicum
Kiromic
Merck
Northwest Biotherapeutics
Glaxo Smith Kline
ImmunoCellular
Tella
Vaxil Bio
Medigene
Market size by Product
CreaVax
Sipuleucel-T (Provenge)
Others
Market size by End User
Pediatrics
Adults
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Dendritic Cell Cancer Vaccine market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Dendritic Cell Cancer Vaccine market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Dendritic Cell Cancer Vaccine companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Dendritic Cell Cancer Vaccine submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Dendritic Cell Cancer Vaccine are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Doses). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Dendritic Cell Cancer Vaccine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Dendritic Cell Cancer Vaccine Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Dendritic Cell Cancer Vaccine Market Size Growth Rate by Product
- 1.4.2 CreaVax
- 1.4.3 Sipuleucel-T (Provenge)
- 1.4.4 Others
- 1.5 Market by End User
- 1.5.1 Global Dendritic Cell Cancer Vaccine Market Size Growth Rate by End User
- 1.5.2 Pediatrics
- 1.5.3 Adults
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Dendritic Cell Cancer Vaccine Market Size
- 2.1.1 Global Dendritic Cell Cancer Vaccine Revenue 2014-2025
- 2.1.2 Global Dendritic Cell Cancer Vaccine Sales 2014-2025
- 2.2 Dendritic Cell Cancer Vaccine Growth Rate by Regions
- 2.2.1 Global Dendritic Cell Cancer Vaccine Sales by Regions
- 2.2.2 Global Dendritic Cell Cancer Vaccine Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Dendritic Cell Cancer Vaccine Sales by Manufacturers
- 3.1.1 Dendritic Cell Cancer Vaccine Sales by Manufacturers
- 3.1.2 Dendritic Cell Cancer Vaccine Sales Market Share by Manufacturers
- 3.1.3 Global Dendritic Cell Cancer Vaccine Market Concentration Ratio (CR5 and HHI)
- 3.2 Dendritic Cell Cancer Vaccine Revenue by Manufacturers
- 3.2.1 Dendritic Cell Cancer Vaccine Revenue by Manufacturers (2014-2019)
- 3.2.2 Dendritic Cell Cancer Vaccine Revenue Share by Manufacturers (2014-2019)
- 3.3 Dendritic Cell Cancer Vaccine Price by Manufacturers
- 3.4 Dendritic Cell Cancer Vaccine Manufacturing Base Distribution, Product Types
- 3.4.1 Dendritic Cell Cancer Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Dendritic Cell Cancer Vaccine Product Type
- 3.4.3 Date of International Manufacturers Enter into Dendritic Cell Cancer Vaccine Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Dendritic Cell Cancer Vaccine Sales by Product
- 4.2 Global Dendritic Cell Cancer Vaccine Revenue by Product
- 4.3 Dendritic Cell Cancer Vaccine Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Dendritic Cell Cancer Vaccine Breakdown Data by End User
6 North America
- 6.1 North America Dendritic Cell Cancer Vaccine by Countries
- 6.1.1 North America Dendritic Cell Cancer Vaccine Sales by Countries
- 6.1.2 North America Dendritic Cell Cancer Vaccine Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Dendritic Cell Cancer Vaccine by Product
- 6.3 North America Dendritic Cell Cancer Vaccine by End User
7 Europe
- 7.1 Europe Dendritic Cell Cancer Vaccine by Countries
- 7.1.1 Europe Dendritic Cell Cancer Vaccine Sales by Countries
- 7.1.2 Europe Dendritic Cell Cancer Vaccine Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Dendritic Cell Cancer Vaccine by Product
- 7.3 Europe Dendritic Cell Cancer Vaccine by End User
8 Asia Pacific
- 8.1 Asia Pacific Dendritic Cell Cancer Vaccine by Countries
- 8.1.1 Asia Pacific Dendritic Cell Cancer Vaccine Sales by Countries
- 8.1.2 Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Dendritic Cell Cancer Vaccine by Product
- 8.3 Asia Pacific Dendritic Cell Cancer Vaccine by End User
9 Central & South America
- 9.1 Central & South America Dendritic Cell Cancer Vaccine by Countries
- 9.1.1 Central & South America Dendritic Cell Cancer Vaccine Sales by Countries
- 9.1.2 Central & South America Dendritic Cell Cancer Vaccine Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Dendritic Cell Cancer Vaccine by Product
- 9.3 Central & South America Dendritic Cell Cancer Vaccine by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Dendritic Cell Cancer Vaccine by Countries
- 10.1.1 Middle East and Africa Dendritic Cell Cancer Vaccine Sales by Countries
- 10.1.2 Middle East and Africa Dendritic Cell Cancer Vaccine Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Dendritic Cell Cancer Vaccine by Product
- 10.3 Middle East and Africa Dendritic Cell Cancer Vaccine by End User
11 Company Profiles
- 11.1 Medigene
- 11.1.1 Medigene Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Medigene Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Medigene Dendritic Cell Cancer Vaccine Products Offered
- 11.1.5 Medigene Recent Development
- 11.2 Activarti
- 11.2.1 Activarti Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Activarti Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Activarti Dendritic Cell Cancer Vaccine Products Offered
- 11.2.5 Activarti Recent Development
- 11.3 Argos Therapeutics
- 11.3.1 Argos Therapeutics Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Argos Therapeutics Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Argos Therapeutics Dendritic Cell Cancer Vaccine Products Offered
- 11.3.5 Argos Therapeutics Recent Development
- 11.4 Batavia Bioservices
- 11.4.1 Batavia Bioservices Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Batavia Bioservices Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Batavia Bioservices Dendritic Cell Cancer Vaccine Products Offered
- 11.4.5 Batavia Bioservices Recent Development
- 11.5 Bellicum Pharmaceuticals
- 11.5.1 Bellicum Pharmaceuticals Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Products Offered
- 11.5.5 Bellicum Pharmaceuticals Recent Development
- 11.6 Creagene
- 11.6.1 Creagene Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Creagene Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Creagene Dendritic Cell Cancer Vaccine Products Offered
- 11.6.5 Creagene Recent Development
- 11.7 DanDrit Biotech
- 11.7.1 DanDrit Biotech Company Details
- 11.7.2 Company Business Overview
- 11.7.3 DanDrit Biotech Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 DanDrit Biotech Dendritic Cell Cancer Vaccine Products Offered
- 11.7.5 DanDrit Biotech Recent Development
- 11.8 DCPrime
- 11.8.1 DCPrime Company Details
- 11.8.2 Company Business Overview
- 11.8.3 DCPrime Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 DCPrime Dendritic Cell Cancer Vaccine Products Offered
- 11.8.5 DCPrime Recent Development
- 11.9 Sanpower Corporation (Dendreon)
- 11.9.1 Sanpower Corporation (Dendreon) Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Sanpower Corporation (Dendreon) Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Sanpower Corporation (Dendreon) Dendritic Cell Cancer Vaccine Products Offered
- 11.9.5 Sanpower Corporation (Dendreon) Recent Development
- 11.10 Elios Therapeutics
- 11.10.1 Elios Therapeutics Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Elios Therapeutics Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Elios Therapeutics Dendritic Cell Cancer Vaccine Products Offered
- 11.10.5 Elios Therapeutics Recent Development
- 11.11 Immunicum
- 11.12 Kiromic
- 11.13 Merck
- 11.14 Northwest Biotherapeutics
- 11.15 Glaxo Smith Kline
- 11.16 ImmunoCellular
- 11.17 Tella
- 11.18 Vaxil Bio
- 11.19 Medigene
12 Future Forecast
- 12.1 Dendritic Cell Cancer Vaccine Market Forecast by Regions
- 12.1.1 Global Dendritic Cell Cancer Vaccine Sales Forecast by Regions 2019-2025
- 12.1.2 Global Dendritic Cell Cancer Vaccine Revenue Forecast by Regions 2019-2025
- 12.2 Dendritic Cell Cancer Vaccine Market Forecast by Product
- 12.2.1 Global Dendritic Cell Cancer Vaccine Sales Forecast by Product 2019-2025
- 12.2.2 Global Dendritic Cell Cancer Vaccine Revenue Forecast by Product 2019-2025
- 12.3 Dendritic Cell Cancer Vaccine Market Forecast by End User
- 12.4 North America Dendritic Cell Cancer Vaccine Forecast
- 12.5 Europe Dendritic Cell Cancer Vaccine Forecast
- 12.6 Asia Pacific Dendritic Cell Cancer Vaccine Forecast
- 12.7 Central & South America Dendritic Cell Cancer Vaccine Forecast
- 12.8 Middle East and Africa Dendritic Cell Cancer Vaccine Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Dendritic Cell Cancer Vaccine Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Dendritic Cell Cancer Vaccine . Industry analysis & Market Report on Dendritic Cell Cancer Vaccine is a syndicated market report, published as Global Dendritic Cell Cancer Vaccine Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Dendritic Cell Cancer Vaccine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
